Inicio › Neuroblastoma › Nueva York
Ensayos clínicos de Neuroblastoma en Nueva York
15 estudios sobre Neuroblastoma buscan participantes en Nueva York.
Ciudades en Nueva York
Texto oficial del estudio (inglés)
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- Columbia University Medical Center, New York
Reclutando
Hasta los 17 · Todos los sexos · Actualizado el 13 nov 2026 · NCT06831552A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- Memorial Sloan Kettering Cancer Center, New York
ReclutandoFase 2Se aceptan voluntarios sanos
Todas las edades · Todos los sexos · Actualizado el 10 nov 2026 · NCT04936529A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
- Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack
- Memorial Sloan Kettering Westchester (Consent only), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- y 1 más
ReclutandoFase 2
Todas las edades · Todos los sexos · Actualizado el 9 nov 2026 · NCT06057948Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
- Memorial Sloan Kettering Cancer Center, New York
ReclutandoFase 1/2
Edades de 1 a 30 · Todos los sexos · Actualizado el 6 nov 2026 · NCT07437963Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- NYU Langone Hospital - Long Island, Mineola
- y 7 más
ReclutandoFase 3
Hasta los 30 · Todos los sexos · Actualizado el 30 oct 2026 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
- New York Medical College ( Site 1023), Valhalla
ReclutandoFase 1/2
6 Months – 25 Years · Todos los sexos · Actualizado el 30 oct 2026 · NCT06395103Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
- Memorial Sloan Kettering Cancer Center, New York
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 5 oct 2026 · NCT00588068N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
- Memorial Sloan Kettering Cancer Center, New York
ReclutandoFase 2
18 Months – 19 Years · Todos los sexos · Actualizado el 28 ago 2026 · NCT06528496Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- y 8 más
ReclutandoFase 3
365 Days – 30 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
ReclutandoFase 1/2
12 Months – 30 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT04851119SPEARHEAD-3 Pediatric Study
- Memorial Sloan Kettering Kids, New York
ReclutandoFase 1/2
Edades de 2 a 21 · Todos los sexos · Actualizado el 11 ago 2026 · NCT05642455Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- Memorial Sloan Kettering Cancer Center, New York
ReclutandoFase 2
Edades de 1 en adelante · Todos los sexos · Actualizado el 29 may 2026 · NCT00107289Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
- New York Medical College, Valhalla
ReclutandoFase 1
Edades de 1 a 30 · Todos los sexos · Actualizado el 15 abr 2026 · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
- Albert Einstein College of Medicine, Children's Hospital at Montefiore, The Bronx
- New York Medical Center/ Maria Fareri Children's Hospital, Valhalla
ReclutandoFase 2
Edades de 1 a 50 · Todos los sexos · Actualizado el 13 mar 2026 · NCT01804634A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's Hospital at Montefiore, The Bronx
ReclutandoFase 2
18 Months – 40 Years · Todos los sexos · Actualizado el 12 ago 2025 · NCT05135975De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.